# Sodium Pyruvate Nasal Spray Treatment of COVID-19 Infection

> **NCT04824365** · PHASE2,PHASE3 · COMPLETED · sponsor: **Cellular Sciences, inc.** · enrollment: 30 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Sodium Pyruvate
- **OTHER:** Saline

## Key facts

- **NCT ID:** NCT04824365
- **Lead sponsor:** Cellular Sciences, inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-12
- **Primary completion:** 2022-08-12
- **Final completion:** 2022-08-12
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2022-11-02

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04824365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04824365, "Sodium Pyruvate Nasal Spray Treatment of COVID-19 Infection". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04824365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*